Therapeutic Area | MeSH |
---|---|
infections | D007239 |
urogenital diseases | D000091642 |
immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SUSTIVA | Bristol Myers Squibb | N-020972 DISCN | 1998-09-17 | 3 products, RLD |
SUSTIVA | Bristol Myers Squibb | N-021360 DISCN | 2002-02-01 | 2 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ATRIPLA | Gilead Sciences | N-021937 DISCN | 2006-07-12 | 1 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
atripla | New Drug Application | 2024-07-09 |
atripla access | Export only | 2021-04-12 |
efavirenz | ANDA | 2024-09-05 |
efavirenz, emtricitabine and tenofovir disoproxil fumarate | ANDA | 2024-06-27 |
efavirenz, lamivudine and tenofovir disoproxil fumarate | ANDA | 2024-05-07 |
sustiva | New Drug Application | 2013-01-02 |
symfi | New Drug Application | 2019-10-15 |
symfi lo | New Drug Application | 2019-10-15 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hiv infections | EFO_0000764 | D015658 | B20 |
hiv | — | D006678 | — |
acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
chronic hepatitis b | EFO_0004239 | D019694 | B18.1 |
hepatitis b | — | D006509 | — |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate, Atripla, Gilead Sciences | |||
8598185 | 2029-04-28 | DP | |
9018192 | 2026-06-13 | U-750, U-1170 | |
9545414 | 2026-06-13 | DP | U-750, U-1170 |
8592397 | 2024-01-13 | DP | U-750, U-1170 |
8716264 | 2024-01-13 | DP | U-257 |
9457036 | 2024-01-13 | DP | U-257 |
9744181 | 2024-01-13 | DP | U-257 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 35 | 76 | 108 | 78 | 71 | 354 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 11 | 16 | 29 | 15 | 27 | 95 |
Hiv | D006678 | — | — | 11 | 12 | 9 | 21 | 23 | 71 |
Infections | D007239 | EFO_0000544 | — | 9 | 18 | 14 | 9 | 12 | 61 |
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 5 | 9 | 8 | 9 | 10 | 40 |
Communicable diseases | D003141 | — | — | 6 | 5 | 6 | 5 | 6 | 27 |
Healthy volunteers/patients | — | — | — | 18 | — | — | 4 | — | 22 |
Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | — | 6 | 8 | 4 | 2 | 19 |
Hepatitis c | D006526 | — | B19.2 | 5 | 3 | 3 | 3 | 6 | 19 |
Hepatitis | D006505 | HP_0012115 | K75.9 | 5 | 2 | 3 | 5 | 5 | 19 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | 1 | 2 | — | 1 | 3 |
Breast feeding | D001942 | — | — | — | — | 1 | — | 1 | 2 |
Pregnancy rate | D018873 | — | — | — | — | 1 | — | — | 1 |
Chronic hepatitis | D006521 | — | K73.9 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | 1 | — | — | 2 | 3 |
Arteritis | D001167 | EFO_0009011 | I77.6 | — | 2 | — | — | — | 2 |
Lymphoma | D008223 | — | C85.9 | 1 | 1 | — | — | — | 2 |
Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 1 | — | — | — | 1 |
Parasitemia | D018512 | — | — | 1 | 1 | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
Aids-related lymphoma | D016483 | EFO_1001365 | — | — | 1 | — | — | — | 1 |
Hepatitis b virus | D006515 | — | — | — | 1 | — | — | — | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pharmacokinetics | D010599 | — | — | 4 | — | — | — | 1 | 5 |
Neoplasms | D009369 | — | C80 | 3 | — | — | — | — | 3 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | — | 1 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | — | — | — | — | 1 |
Toxoplasmosis | D014123 | EFO_0007517 | B58 | 1 | — | — | — | — | 1 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
Premature obstetric labor | D007752 | — | O60 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sleep wake disorders | D012893 | — | G47 | — | — | — | — | 2 | 2 |
Depression | D003863 | — | F33.9 | — | — | — | — | 2 | 2 |
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | — | — | 1 | 1 |
Penicillium chrysogenum | D010408 | NCBITaxon_5076 | — | — | — | — | — | 1 | 1 |
Biological availability | D001682 | — | — | — | — | — | — | 1 | 1 |
Osteoporosis | D010024 | HP_0000939 | M81.0 | — | — | — | — | 1 | 1 |
Contraception behavior | D003268 | — | — | — | — | — | — | 1 | 1 |
Sustained virologic response | D000072230 | — | — | — | — | — | — | 1 | 1 |
Neurobehavioral manifestations | D019954 | EFO_0004364 | — | — | — | — | — | 1 | 1 |
Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
Drug common name | Efavirenz |
INN | efavirenz |
Description | Efavirenz is 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection. It has a role as a HIV-1 reverse transcriptase inhibitor and an antiviral drug. It is a benzoxazine, an acetylenic compound, an organochlorine compound, an organofluorine compound and a member of cyclopropanes. |
Classification | Small molecule |
Drug class | Fc fusion protein; antivirals: non-nucleoside reverse transcriptase inhibitors; benzoxazinone derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1 |
PDB | — |
CAS-ID | 154598-52-4 |
RxCUI | — |
ChEMBL ID | CHEMBL223228 |
ChEBI ID | 119486 |
PubChem CID | 64139 |
DrugBank | DB00625 |
UNII ID | JE6H2O27P8 (ChemIDplus, GSRS) |